171 related articles for article (PubMed ID: 2849657)
1. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.
Little PJ; Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1988 Dec; 247(3):1046-51. PubMed ID: 2849657
[TBL] [Abstract][Full Text] [Related]
2. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Lichtman AH; Cook SA; Martin BR
J Pharmacol Exp Ther; 1996 Feb; 276(2):585-93. PubMed ID: 8632325
[TBL] [Abstract][Full Text] [Related]
3. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.
Howlett AC; Johnson MR; Melvin LS; Milne GM
Mol Pharmacol; 1988 Mar; 33(3):297-302. PubMed ID: 3352594
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of indole- and pyrrole-derived cannabinoids.
Wiley JL; Compton DR; Dai D; Lainton JA; Phillips M; Huffman JW; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):995-1004. PubMed ID: 9618400
[TBL] [Abstract][Full Text] [Related]
6. Spinal and supraspinal components of cannabinoid-induced antinociception.
Lichtman AH; Martin BR
J Pharmacol Exp Ther; 1991 Aug; 258(2):517-23. PubMed ID: 1650831
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids.
Martin BR; Compton DR; Little PJ; Martin TJ; Beardsley PM
NIDA Res Monogr; 1987; 79():108-22. PubMed ID: 2830532
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
Howlett AC; Fleming RM
Mol Pharmacol; 1984 Nov; 26(3):532-8. PubMed ID: 6092901
[TBL] [Abstract][Full Text] [Related]
11. Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison.
Järbe TU; Hiltunen AJ; Mathis DA; Hanŭs L; Breuer A; Mechoulam R
J Pharmacol Exp Ther; 1993 Feb; 264(2):561-9. PubMed ID: 8382275
[TBL] [Abstract][Full Text] [Related]
12. Cannabis: pharmacology and toxicology in animals and humans.
Adams IB; Martin BR
Addiction; 1996 Nov; 91(11):1585-614. PubMed ID: 8972919
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
Compton DR; Rice KC; De Costa BR; Razdan RK; Melvin LS; Johnson MR; Martin BR
J Pharmacol Exp Ther; 1993 Apr; 265(1):218-26. PubMed ID: 8474008
[TBL] [Abstract][Full Text] [Related]
15. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
17. 1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.
Dajani EZ; Larsen KR; Taylor J; Dajani NE; Shahwan TG; Neeleman SD; Taylor MS; Dayton MT; Mir GN
J Pharmacol Exp Ther; 1999 Oct; 291(1):31-8. PubMed ID: 10490883
[TBL] [Abstract][Full Text] [Related]
18. Stereochemical requirements for cannabimimetic activity.
Mechoulam R; Lander N; Srebnik M; Breuer A; Segal M; Feigenbaum JJ; Jarbe TU; Consroe P
NIDA Res Monogr; 1987; 79():15-30. PubMed ID: 3125475
[TBL] [Abstract][Full Text] [Related]
19. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity.
Lichtman AH; Smith PB; Martin BR
Pain; 1992 Oct; 51(1):19-26. PubMed ID: 1454400
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of delta 9-THC carbamate.
Little PJ; Kaplan NC; Martin BR
Alcohol Drug Res; 1987; 7(5-6):517-23. PubMed ID: 3040025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
